Bladder Cancer Treatment Market is expected to hit USD 7.52 Bn by 2029 at a CAGR of 9.2 percent – says Maximize Market Research
May 30, 2023 08:08 ET
|
MAXIMIZE MARKET RESEARCH PRIVATE LIMITED
Pune, May 30, 2023 (GLOBE NEWSWIRE) -- A global Healthcare research and business-consulting firm, Maximize Market Research, has published a market intelligence report on the “Bladder Cancer...
The Worldwide IVD Market, 2019-2024
December 06, 2019 04:25 ET
|
Research and Markets
Dublin, Dec. 06, 2019 (GLOBE NEWSWIRE) -- The "Current IVD Market Trends" report has been added to ResearchAndMarkets.com's offering. This report is an update on the worldwide...
Tymidinkinas 1 kan användas för tidigt terapisvar vid behandling av bröstcancer
September 18, 2019 11:10 ET
|
AroCell AB
Patienter behandlade med Epirubicin och Docetaxel före operationen följdes med deras tymidinkinas (TK1) nivåer i blodet för att direkt observera behandlingssvaret. Resultaten visar att en TK1-baserat...
Thymidine Kinase 1 can be used for early detection of therapy response in breast cancer treatment
September 18, 2019 11:10 ET
|
AroCell AB
Patients treated with Epirubicin and Docetaxel before surgery were followed by their thymidine kinase (TK1) levels in blood to directly observe treatment response. The results show that a TK1-based...
AroCell utökar med en Regulatory Affairs Director
September 11, 2019 08:00 ET
|
AroCell AB
AroCell AB (publ.) tillkännager i dag att Peter Löwendahl ingår i ledningsgruppen som Senior Director Regulatory Affairs. Peter Löwendahl kommer att leda och utveckla AroCells regulatoriska strategi...
AroCell expands with a Regulatory Affairs Director
September 11, 2019 08:00 ET
|
AroCell AB
AroCell AB (publ.) announces today that Peter Löwendahl joins the management team as senior director regulatory affairs. Peter Löwendahl will lead and develop AroCell’s regulatory strategy with focus...
AroCell AB (publ) Delårsrapport 1 januari – 30 juni 2019
August 21, 2019 02:00 ET
|
AroCell AB
VD-ORD ”Det är med glädje som jag kan konstatera att det andra kvartalet 2019 blev ett av det mest spännande och aktiva kvartal i AroCells historia. Målet att etablera AroCell som den givne partnern...
AroCell AB (publ) Interim Report January 1st to June 30th 2019
August 21, 2019 02:00 ET
|
AroCell AB
Word from the CEO “It is with pleasure that I can say that the second quarter of 2019 became one of the most exciting and active quarters in AroCell's history. The goal of establishing AroCell as...
AroCell tecknar ett nytt distributörsavtal i USA och Kanada
August 06, 2019 02:15 ET
|
AroCell AB
AroCell AB (publ) meddelade idag att man har tecknat ett distributionsavtal med Diapharma Group i West Chester Ohio för marknadsföring och distribution av AroCell TK 210™ ELISA i USA och Kanada. ...
AroCell signs a new distributor agreement in the USA and Canada
August 06, 2019 02:15 ET
|
AroCell AB
AroCell AB (publ) announced today that it has signed a distribution agreement with Diapharma Group of West Chester Ohio for the promotion and distribution of the AroCell TK 210™ ELISA in the United...